Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.53 |
| ▸ | PGR | P06401 | 9/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496799 | 0.79 | NR3C1 (0.59) | NR3C1PGR | |
| SCHEMBL5500106 | 0.77 | PGR (0.63) | NR3C1PGR | |
| SCHEMBL5497917 | 0.77 | NR3C1 (0.61) | NR3C1PGR | |
| SCHEMBL21624352 | 0.75 | MOGAT2 (0.34) | NR3C1PGRCES1ALDH1A1 | |
| SCHEMBL5501180 | 0.72 | NR3C1 (0.57) | NR3C1PGR | |
| SCHEMBL5500730 | 0.72 | NR3C1 (0.55) | NR3C1PGRCES1ALDH1A1 | |
| SCHEMBL5501074 | 0.70 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL5500759 | 0.70 | NR3C1 (0.55) | NR3C1PGR | |
| SCHEMBL27685677 | 0.69 | NR3C1 (0.38) | NR3C1PGR | |
| SCHEMBL5501885 | 0.69 | NR3C1 (0.33) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | NR3C1 533/4885PGR 953/4885CES1 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.